ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
06 3월 2024 - 6:30AM
ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”)
(Nasdaq: ALXO), an immuno-oncology company developing therapies
that block the CD47 immune checkpoint pathway, today announced that
two clinical abstracts have been accepted for presentation at the
American Association for Cancer Research (“AACR”) Annual Meeting,
which will be held in San Diego from April 5-10, 2024.
Session titles and information for the two
abstracts are listed below and are now available on the AACR online
program planner.
A Phase 1 investigator-initiated trial of
evorpacept (ALX148), lenalidomide and rituximab for patients with
relapsed or refractory B-cell non-Hodgkin lymphoma Session
Title: Clinical Trials Minisymposium (Oral Presentation) / Novel
Agents and Emerging Therapeutic Strategies Session Date and Time:
Tuesday, April 9, 2024 2:30 PM – 4:30 PM PT Abstract: CT037
Phase 1 study of azacitidine in
combination with evorpacept for higher-risk myelodysplastic
syndrome (MDS) Session Title: Phase I Clinical Trials 1
Session Date and Time: Monday April 8, 2024 9:00 AM – 12:30 PM PT
Location: Poster Section 48 Poster Board Number: 10 Abstract:
CT060
Copies of the presentations will be available on
ALX Oncology’s website at
https://alxoncology.com/science/#publications following
presentation at the meeting.
About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage
immuno-oncology company focused on helping patients fight cancer by
developing therapies that block the CD47 immune checkpoint
inhibitor and bridge the innate and adaptive immune system. ALX
Oncology’s lead product candidate, evorpacept, is a next generation
CD47 blocking therapeutic that combines a high-affinity CD47
binding domain with an inactivated, proprietary Fc domain. To date,
evorpacept has been dosed in over 500 subjects and has demonstrated
promising activity and favorable tolerability profile across a
range of hematologic and solid malignancies in combination with
various leading anti-cancer antibodies. ALX Oncology is currently
focusing on combining evorpacept with anti-cancer antibodies, ADCs,
and PD-1/PD-L1 immune checkpoint inhibitors.
Investor and Media Contact:
Caitlyn Doherty
Manager, Investor Relations and Corporate Communications, ALX Oncology
cdoherty@alxoncology.com
(650) 466-7125
ALX Oncology (NASDAQ:ALXO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
ALX Oncology (NASDAQ:ALXO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024